PLAU and myeloid sarcoma: Chedraui Pet al. demonstrated that postmenopausal women with MS displayed higher IL-6 (inflammation) and lower urokinase-type plasminogen activator levels (endothelial dysfunction) which were mainly related to metabolic abnormalities and led to the occurrence of 2 components of MS at the same time [30].